Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 391-395

  Colombo, T ^a   Parisi, I ^a   Zucchetti, M ^a   Sessa, C ^b   Goldhirsch, A ^c   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Docetaxel; Doxorubicin; Interaction; Mice; Paclitaxel; Pharmacokinetics

Indexed keywords

CREMOPHOR; DOCETAXEL; DOXORUBICIN; DRUG VEHICLE; PACLITAXEL; POLYSORBATE; TAXANE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032907443     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008309916974     Document Type: Article

References (22)

1. Colombo T, Gonzalez Paz O, Zucchetti M et al. Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 1996; 7: 801-5.
2. Holmes FA, Valero V, Walters RS et al. The M. D. Anderson Cancer Center experience with taxol in metastatic breast cancer. J Natl Cancer Inst 1993; Monographs: 161-9.
3. Gianni L, Munzone E, Capri G et al. Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study [see comments]. J Clin Oncol 1995; 13: 2688-99.
4. Amadori D, Frassineti GL, Zoli W et al. A phase I-II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Semin Oncol 1996; 23: 19-23.
5. Gianni L, Capri G. Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Semin Oncol 1997; 24: S1-S3.
6. Clemons M, Leahy M, Valle J et al. Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur J Cancer 1997; 33: 2183-93.
7. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. [Review] [30 refs]. Semin Oncol 1997; 24: S13-S19.
8. Gehl J, Boesgaard M, Paaske T et al. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 1996; 7: 687-93.
9. Hortobagyi GN, Willey J, Rahman Z et al. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 1997; 24: S17-S65.
10. Dombernowsky P, Gehl J, Boesgaard M et al. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. [Review] [17 refs]. Semin Oncol 1996; 23: 13-8.
11. Holmes FA, Madden T, Newman RA et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 2713-21.
12. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15.
13. Broggini M, Italia C, Colombo T et al. Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984; 68: 739-47.
14. Holmes FA. Update: the M. D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Semin Oncol 1995; 22: 9-15.
15. Eisenhauer EA and Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. [Review] [188 refs]. Drugs 1998; 55: 5-30.
16. Bhalla K, Huang Y, Tang C et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994; 8: 465-75.
17. Parekh H and Simpkins H. The transport and binding of Taxol. [Review] [47 refs]. Gen Pharmacol 1997; 29: 167-72.
18. Rischin D, Webster LK, Millward MJ et al. Cremophor pharmacokinetics in patients receiving three-, six-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 1996; 88: 1297-301.
19. Gottesman MM and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. [Review] [348 refs]. Annu Rev Biochem 1993; 62: 385-427.
20. Bradley G and Ling V. P-glycoprotein, multidrug resistance and tumor progression. [Review] [46 refs]. Cancer Metastasis Rev 1994; 13: 223-33.
21. Nygren P, Csoka K, Jonsson B et al. The cytotoxic activity of taxol in primary cultures of tumour cells from patients is partly mediated by cremophor EL. Br J Cancer 1995; 71: 478-81.
22. Webster LK, Linsenmeyer ME, Rischin D et al. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemoth Pharmacol 1997; 39: 557-60.